Volker Heinemann

Presentation(s):

• SO-16: FIRE-4 (AIO-KRK-0114): Randomized study for a switch maintenance concept with 5-FU plus bevacizumab after induction treatment with FOLFIRI plus cetuximab versus continued treatment with FOLFIRI plus cetuximab-secondary endpoint

  Friday, July 1, 2022
  08:00 – 08:08